» Articles » PMID: 15741788

Multiple Psychotropic Medication Use for Youths: a Two-state Comparison

Overview
Publisher Mary Ann Liebert
Date 2005 Mar 3
PMID 15741788
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of this study was to compare multiple psychotropic use among youths enrolled in two U.S. mid-Atlantic state Medicaid and state Children's Health Insurance Programs (SCHIP).

Methods: Administrative data were used to examine multiple psychotropic use among youths less than 20 years of age and who were continuously enrolled in Medicaid or SCHIP programs in two states during 1999. Multiple psychotropic use referred to multiclass combinations and was defined by the number of months of multiple use. Main outcome measures were the prevalence of multiple psychotropic use and months of multiple use. Demographic and clinical characteristics, mental health visits, and common combinations were examined according to months of multiple use.

Results: Among continuously enrolled youths, 21%-22% had at least one mental health-related visit, 8%-10% received a psychotropic medication, and 2%-3% received multiple psychotropic medications. Nearly one third (28%-30%) of youths with any psychotropic use received multiple medications, of which almost half was for 5-12 months. Multiclass use was more common in male, white, aged 10-14, disabled, and foster-care youths. Stimulants with antidepressants, antipsychotics, or alpha-agonists were the most common combinations.

Conclusions: Multiple use occurred in nearly one third of youths with any psychotropic treatment. Additional research is needed to investigate switching patterns and the effectiveness of combined pharmacotherapy.

Citing Articles

The Utah psychotropic oversight program: collaboratively addressing antipsychotic use within youth in foster care without prior authorization.

Monson E, Shastri S, Chen D, Madden S, Keeshin B Front Psychiatry. 2023; 14:1271165.

PMID: 38025462 PMC: 10654962. DOI: 10.3389/fpsyt.2023.1271165.


Pediatric Psychotropic Polypharmacy: An Evaluation of the Correlates and Prevalence Across Assessment Cycles in the National Health and Nutrition Examination Survey.

Bilsky S, Blumenthal H, Ramadan B, Lewis S, Leen-Feldner E J Child Adolesc Psychopharmacol. 2022; 32(8):416-425.

PMID: 36074100 PMC: 9639228. DOI: 10.1089/cap.2022.0010.


Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone.

Taurines R, Fekete S, Preuss-Wiedenhoff A, Warnke A, Wewetzer C, Plener P J Neural Transm (Vienna). 2022; 129(5-6):689-701.

PMID: 35303169 PMC: 9188514. DOI: 10.1007/s00702-022-02485-6.


Manuscript: Defining Quality Standards for Intensive Home Based Treatment Programs for Youth with Serious Emotional Disorders.

Bruns E, Benjamin P, Shepler R, Kellogg M, Pluckebaum H, Woolston J Adm Policy Ment Health. 2021; 48(6):1065-1088.

PMID: 34241737 PMC: 8267760. DOI: 10.1007/s10488-021-01116-8.


Psychotropic Polypharmacy in the US Pediatric Population: A Methodologic Critique and Commentary.

Zito J, Zhu Y, Safer D Front Psychiatry. 2021; 12:644741.

PMID: 34194346 PMC: 8236612. DOI: 10.3389/fpsyt.2021.644741.